New malaria vaccine for pregnant women enters human testing

NCT ID NCT02658253

Completed ⭐️ VACCINE ⭐️ Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a vaccine called PRIMVAC, designed to prevent malaria during pregnancy. Researchers gave three different doses to 68 healthy adults in France and Burkina Faso to check safety and immune response. The vaccine targets a protein that helps malaria parasites attach to the placenta.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRIMVAC vaccine (a protein from the malaria parasite) with either Alhydrogel or GLA-SE adjuvant
What this could lead to: If successful, this could lead to a vaccine that protects pregnant women from placental malaria, preventing severe complications for mothers and babies.
What could go wrong: This is an early Phase 1 trial with only 68 participants, focused on safety and immune response, not yet on preventing disease. The vaccine may not produce strong enough immunity or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA

Contacts and locations

Locations

CIC 1417

Paris, 75679, France
CNRFP

Ouagadougou, BP 2208, Burkina Faso

More trials for these conditions

Other studies related to the condition(s) this trial covers.